Tamsulosin HCl + Solifenacin Succinate + EC905
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Phase 1
Conditions
Phase 1, Healthy, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Trial Timeline
Mar 1, 2009 → Jul 1, 2009
NCT ID
NCT02634489About Tamsulosin HCl + Solifenacin Succinate + EC905
Tamsulosin HCl + Solifenacin Succinate + EC905 is a phase 1 stage product being developed by Astellas Pharma for Phase 1. The current trial status is completed. This product is registered under clinical trial identifier NCT02634489. Target conditions include Phase 1, Healthy, Benign Prostatic Hyperplasia.
What happened to similar drugs?
7 of 15 similar drugs in Phase 1 were approved
Approved (7) Terminated (2) Active (6)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02634489 | Phase 1 | Completed |
Competing Products
20 competing products in Phase 1
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 36 |
| solifenacin succinate + mirabegron + mirabegron/solifenacin succinate | Astellas Pharma | Phase 1 | 29 |
| Graceptor® | Astellas Pharma | Pre-clinical | 26 |
| Lemborexant + Placebo | Eisai | Approved | 50 |
| BIW-8962 | Kyowa Kirin | Phase 1/2 | 24 |
| Acalabrutinib | AstraZeneca | Phase 1/2 | 36 |
| Sacituzumab tirumotecan | Merck | Phase 2 | 42 |
| progesterone + Progesterone | Merck | Approved | 39 |
| Asciminib | Novartis | Pre-clinical | 30 |
| Nilotinib | Novartis | Phase 3 | 40 |
| Imatinib mesylate | Novartis | Phase 3 | 32 |
| Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib Mesylate | Novartis | Phase 3 | 32 |
| ribociclib + Trametinib | Novartis | Phase 1 | 21 |
| Nilotinib | Novartis | Approved | 43 |
| Imatinib | Novartis | Phase 3 | 40 |
| Nilotinib | Novartis | Approved | 43 |
| Gleevec | Novartis | Phase 2 | 35 |
| Nilotinib + Ruxolitinib | Novartis | Phase 1/2 | 32 |
| ABL001 | Novartis | Phase 3 | 40 |
| asciminib | Novartis | Phase 2 | 39 |